Overview
Breast milk is the most effective single intervention for NEC prevention. Human milk oligosaccharides (HMOs) — the third most abundant component of breast milk — are selectively metabolized by Bifidobacteria, establishing the protective neonatal microbiome. Formula-fed preterm infants have dramatically higher NEC rates.
Mechanism
- HMOs as selective prebiotics (Primitive 5): Over 200 distinct HMO structures are metabolized almost exclusively by Bifidobacterium species, establishing ecological dominance of beneficial taxa
- Lactoferrin (Primitive 8): Breast milk lactoferrin sequesters free iron, starving siderophore-dependent pathogens
- Secretory IgA: Coats pathogenic bacteria, preventing adhesion and translocation
- AHR ligands: Activate aryl hydrocarbon receptor signaling in intestinal epithelium, promoting barrier integrity and innate immune development
- Zinc (Primitive 2): Supports epithelial barrier function and metallothionein expression in the neonatal gut
Clinical Evidence
Epidemiological and prospective cohort data consistently demonstrate:
- Dose-response relationship between breast milk volume and NEC risk reduction
- Exclusive breast milk feeding reduces NEC incidence by approximately 50-80% compared to formula
- Donor breast milk, while less protective than mother's own milk, still significantly reduces NEC vs. formula
Clinical Considerations
- Mother's own milk is preferred; donor milk is second-line
- Fortification of breast milk for VLBW infants should use human-milk-based fortifiers when possible
- When breast milk is unavailable, HMO-supplemented formula is an emerging option
- Breast milk feeding should begin as early as possible, even in trophic feeding volumes